Literature DB >> 11157424

Psychiatric effects of cannabis.

A Johns1.   

Abstract

BACKGROUND: Cannabis is commonly regarded as an innocuous drug and the prevalence of lifetime and regular use has increased in most developed countries. However, accumulative evidence highlights the risks of dependence and other adverse effects, particularly among people with pre-existing psychiatric disorders. AIMS: To re-evaluate the adverse effects of cannabis in the general population and among vulnerable individuals, including those with serious psychiatric disorders.
METHOD: A wide-ranging review of the topics related to these issues. Results and conclusions An appreciable proportion of cannabis users report short-lived adverse effects, including psychotic states following heavy consumption, and regular users are at risk of dependence. People with major mental illnesses such as schizophrenia are especially vulnerable in that cannabis generally provokes relapse and aggravates existing symptoms. Health workers need to recognise, and respond to, the adverse effects of cannabis on mental health.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11157424     DOI: 10.1192/bjp.178.2.116

Source DB:  PubMed          Journal:  Br J Psychiatry        ISSN: 0007-1250            Impact factor:   9.319


  65 in total

Review 1.  Cannabis control: costs outweigh the benefits. For.

Authors:  Alex Wodak; Craig Reinarman; Peter D A Cohen; Colin Drummond
Journal:  BMJ       Date:  2002-01-12

2.  Self reported cannabis use as a risk factor for schizophrenia in Swedish conscripts of 1969: historical cohort study.

Authors:  Stanley Zammit; Peter Allebeck; Sven Andreasson; Ingvar Lundberg; Glyn Lewis
Journal:  BMJ       Date:  2002-11-23

3.  Gene-environment interplay in affect and dementia: emotional modulation of cognitive expression in personal outcomes.

Authors:  T Palomo; R J Beninger; R M Kostrzewa; T Archer
Journal:  Neurotox Res       Date:  2004       Impact factor: 3.911

Review 4.  Cannabinoid modulation of noradrenergic circuits: implications for psychiatric disorders.

Authors:  Ana Franky Carvalho; Elisabeth J Van Bockstaele
Journal:  Prog Neuropsychopharmacol Biol Psychiatry       Date:  2012-01-24       Impact factor: 5.067

5.  Structural network topology revealed by white matter tractography in cannabis users: a graph theoretical analysis.

Authors:  Dae-Jin Kim; Patrick D Skosnik; Hu Cheng; Ben J Pruce; Margaret S Brumbaugh; Jennifer M Vollmer; William P Hetrick; Brian F O'Donnell; Olaf Sporns; Aina Puce; Sharlene D Newman
Journal:  Brain Connect       Date:  2012-02-24

Review 6.  Blurred boundaries: the therapeutics and politics of medical marijuana.

Authors:  J Michael Bostwick
Journal:  Mayo Clin Proc       Date:  2012-02       Impact factor: 7.616

7.  Antidepressant-like effect of delta9-tetrahydrocannabinol and other cannabinoids isolated from Cannabis sativa L.

Authors:  Abir T El-Alfy; Kelly Ivey; Keisha Robinson; Safwat Ahmed; Mohamed Radwan; Desmond Slade; Ikhlas Khan; Mahmoud ElSohly; Samir Ross
Journal:  Pharmacol Biochem Behav       Date:  2010-03-21       Impact factor: 3.533

Review 8.  [The endogenous cannabinoid system. Therapeutic implications for neurologic and psychiatric disorders].

Authors:  U Schneider; J Seifert; M Karst; J Schlimme; K Cimander; K R Müller-Vahl
Journal:  Nervenarzt       Date:  2005-09       Impact factor: 1.214

9.  Subjective and physiological effects after controlled Sativex and oral THC administration.

Authors:  E L Karschner; W D Darwin; R P McMahon; F Liu; S Wright; R S Goodwin; M A Huestis
Journal:  Clin Pharmacol Ther       Date:  2011-02-02       Impact factor: 6.875

10.  Antidepressant-like effects of cannabidiol in mice: possible involvement of 5-HT1A receptors.

Authors:  T V Zanelati; C Biojone; F A Moreira; F S Guimarães; Sâmia R L Joca
Journal:  Br J Pharmacol       Date:  2009-12-04       Impact factor: 8.739

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.